2026-525176-26-00
Recruiting
Phase 1
Study to Learn How Safe EV25 is and the Amount of EV25 in the Body Over a Period of Time, When Given as a Single Dose to Adult Healthy People [CCI]
Eradivir Inc.0 sites16 target enrollmentStarted: April 15, 2026Last updated:
Overview
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Eradivir Inc.
- Enrollment
- 16
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
-
Scientific
Eradivir Inc.
Similar Trials
Active, not recruiting
Phase 1
A study to find how well VES001 works and how safe it is in participants with GRN -frontotemporal dementia (GRN-FTD) showing no symptoms2024-513258-31-00Vesper Bio ApS, Vesper Bio ApS3
Active, not recruiting
Phase 1
A study to investigate the safety, the amount that reaches the bloodstream and the effects on the body of JNJ-64619178 in people with advanced cancers2024-515254-24-00Janssen Cilag International74
Completed
Phase 1
Study is designed to assess the safety and tolerability of ceralasertib at increasing doses in combination with other anti-cancer treatment in patients with advanced tumours2023-505006-41-00AstraZeneca AB100
Not yet recruiting
Phase 1
Study to evaluate the safety, tolerability, maximum tolerated dose and clinical activity of TNB-383B when given to patients with multiple myeloma2023-506993-11-00AbbVie Deutschland GmbH & Co. KG22
Recruiting
Phase 1
A study to learn more about the safety and effects of a new blood-thinning medicine, given alone and together with another blood-thinner, in healthy adultsatrial fibrillationtransient ischemic attack (TIA)ischemic stroke2025-524043-12-00Bayer AG72